Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1995 Dec;69(12):7601–7605. doi: 10.1128/jvi.69.12.7601-7605.1995

Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus.

A McGoldrick 1, A J Macadam 1, G Dunn 1, A Rowe 1, J Burlison 1, P D Minor 1, J Meredith 1, D J Evans 1, J W Almond 1
PMCID: PMC189699  PMID: 7494267

Abstract

Of the 55 point mutations which distinguish the type 1 poliovirus vaccine strain (Sabin 1) from its neurovirulent progenitor (P1/Mahoney), two have been strongly implicated by previous studies as determinants of the attenuation phenotype. A change of an A to a G at position 480, located within the 5' noncoding region, has been suggested to be the major attenuating mutation, analogous to the mutations at positions 481 and 472 in poliovirus types 2 and 3, respectively. In addition, the change of a U to a C at position 6203, resulting in an amino acid change in the polymerase protein 3D, has also been implicated as a determinant of attenuation, albeit to a lesser extent. To assess the contributions of these mutations to attenuation and temperature sensitivity, reciprocal changes were generated at these positions in infectious cDNA clones of Sabin 1 and P1/Mahoney. Assays in tissue culture and primates indicated that the two mutations make some contribution to the temperature sensitivity of the Sabin 1 strain but that neither is a strong determinant of attenuation.

Full Text

The Full Text of this article is available as a PDF (167.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bouchard M. J., Lam D. H., Racaniello V. R. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J Virol. 1995 Aug;69(8):4972–4978. doi: 10.1128/jvi.69.8.4972-4978.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Christodoulou C., Colbere-Garapin F., Macadam A., Taffs L. F., Marsden S., Minor P., Horaud F. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J Virol. 1990 Oct;64(10):4922–4929. doi: 10.1128/jvi.64.10.4922-4929.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dunn G., Begg N. T., Cammack N., Minor P. D. Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. J Med Virol. 1990 Oct;32(2):92–95. doi: 10.1002/jmv.1890320205. [DOI] [PubMed] [Google Scholar]
  4. Evans D. M., Dunn G., Minor P. D., Schild G. C., Cann A. J., Stanway G., Almond J. W., Currey K., Maizel J. V., Jr Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature. 1985 Apr 11;314(6011):548–550. doi: 10.1038/314548a0. [DOI] [PubMed] [Google Scholar]
  5. Furione M., Guillot S., Otelea D., Balanant J., Candrea A., Crainic R. Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology. 1993 Sep;196(1):199–208. doi: 10.1006/viro.1993.1468. [DOI] [PubMed] [Google Scholar]
  6. Horie H., Koike S., Kurata T., Sato-Yoshida Y., Ise I., Ota Y., Abe S., Hioki K., Kato H., Taya C. Transgenic mice carrying the human poliovirus receptor: new animal models for study of poliovirus neurovirulence. J Virol. 1994 Feb;68(2):681–688. doi: 10.1128/jvi.68.2.681-688.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Joce R., Wood D., Brown D., Begg N. Paralytic poliomyelitis in England and Wales, 1985-91. BMJ. 1992 Jul 11;305(6845):79–82. doi: 10.1136/bmj.305.6845.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kawamura N., Kohara M., Abe S., Komatsu T., Tago K., Arita M., Nomoto A. Determinants in the 5' noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol. 1989 Mar;63(3):1302–1309. doi: 10.1128/jvi.63.3.1302-1309.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Macadam A. J., Arnold C., Howlett J., John A., Marsden S., Taffs F., Reeve P., Hamada N., Wareham K., Almond J. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology. 1989 Oct;172(2):408–414. doi: 10.1016/0042-6822(89)90183-9. [DOI] [PubMed] [Google Scholar]
  10. Macadam A. J., Ferguson G., Burlison J., Stone D., Skuce R., Almond J. W., Minor P. D. Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture. Virology. 1992 Aug;189(2):415–422. doi: 10.1016/0042-6822(92)90565-7. [DOI] [PubMed] [Google Scholar]
  11. Macadam A. J., Pollard S. R., Ferguson G., Dunn G., Skuce R., Almond J. W., Minor P. D. The 5' noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology. 1991 Apr;181(2):451–458. doi: 10.1016/0042-6822(91)90877-e. [DOI] [PubMed] [Google Scholar]
  12. Macadam A. J., Pollard S. R., Ferguson G., Skuce R., Wood D., Almond J. W., Minor P. D. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology. 1993 Jan;192(1):18–26. doi: 10.1006/viro.1993.1003. [DOI] [PubMed] [Google Scholar]
  13. Minor P. D., Macadam A., Cammack N., Dunn G., Almond J. W. Molecular biology and the control of viral vaccines. FEMS Microbiol Immunol. 1990 Nov;2(4):207–213. doi: 10.1111/j.1574-6968.1990.tb03521.x. [DOI] [PubMed] [Google Scholar]
  14. Nomoto A., Omata T., Toyoda H., Kuge S., Horie H., Kataoka Y., Genba Y., Nakano Y., Imura N. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc Natl Acad Sci U S A. 1982 Oct;79(19):5793–5797. doi: 10.1073/pnas.79.19.5793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ogra P. L., Faden H. S., Abraham R., Duffy L. C., Sun M., Minor P. D. Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. J Infect Dis. 1991 Jul;164(1):191–194. doi: 10.1093/infdis/164.1.191. [DOI] [PubMed] [Google Scholar]
  16. Omata T., Kohara M., Kuge S., Komatsu T., Abe S., Semler B. L., Kameda A., Itoh H., Arita M., Wimmer E. Genetic analysis of the attenuation phenotype of poliovirus type 1. J Virol. 1986 May;58(2):348–358. doi: 10.1128/jvi.58.2.348-358.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Otelea D., Guillot S., Furione M., Combiescu A. A., Balanant J., Candrea A., Crainic R. Genomic modifications in naturally occurring neurovirulent revertants of Sabin 1 polioviruses. Dev Biol Stand. 1993;78:33–38. [PubMed] [Google Scholar]
  18. Pollard S. R., Dunn G., Cammack N., Minor P. D., Almond J. W. Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. J Virol. 1989 Nov;63(11):4949–4951. doi: 10.1128/jvi.63.11.4949-4951.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Racaniello V. R., Baltimore D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science. 1981 Nov 20;214(4523):916–919. doi: 10.1126/science.6272391. [DOI] [PubMed] [Google Scholar]
  20. Ren R. B., Moss E. G., Racaniello V. R. Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J Virol. 1991 Mar;65(3):1377–1382. doi: 10.1128/jvi.65.3.1377-1382.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rezapkin G. V., Chumakov K. M., Lu Z., Ran Y., Dragunsky E. M., Levenbook I. S. Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine. Virology. 1994 Jul;202(1):370–378. doi: 10.1006/viro.1994.1353. [DOI] [PubMed] [Google Scholar]
  22. SALK J. E., KRECH U., YOUNGNER J. S., BENNETT B. L., LEWIS L. J., BAZELEY P. L. Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am J Public Health Nations Health. 1954 May;44(5):563–570. doi: 10.2105/ajph.44.5.563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sabin A. B. Oral poliovirus vaccine. History of its development and prospects for eradication of poliomyelitis. JAMA. 1965 Nov 22;194(8):872–876. doi: 10.1001/jama.194.8.872. [DOI] [PubMed] [Google Scholar]
  24. Skinner M. A., Racaniello V. R., Dunn G., Cooper J., Minor P. D., Almond J. W. New model for the secondary structure of the 5' non-coding RNA of poliovirus is supported by biochemical and genetic data that also show that RNA secondary structure is important in neurovirulence. J Mol Biol. 1989 May 20;207(2):379–392. doi: 10.1016/0022-2836(89)90261-1. [DOI] [PubMed] [Google Scholar]
  25. Stanway G., Hughes P. J., Mountford R. C., Reeve P., Minor P. D., Schild G. C., Almond J. W. Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b. Proc Natl Acad Sci U S A. 1984 Mar;81(5):1539–1543. doi: 10.1073/pnas.81.5.1539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Stanway G., Hughes P. J., Westrop G. D., Evans D. M., Dunn G., Minor P. D., Schild G. C., Almond J. W. Construction of poliovirus intertypic recombinants by use of cDNA. J Virol. 1986 Mar;57(3):1187–1190. doi: 10.1128/jvi.57.3.1187-1190.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sutter R. W., Patriarca P. A., Brogan S., Malankar P. G., Pallansch M. A., Kew O. M., Bass A. G., Cochi S. L., Alexander J. P., Hall D. B. Outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among fully vaccinated children. Lancet. 1991 Sep 21;338(8769):715–720. doi: 10.1016/0140-6736(91)91442-w. [DOI] [PubMed] [Google Scholar]
  28. Tardy-Panit M., Blondel B., Martin A., Tekaia F., Horaud F., Delpeyroux F. A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice. J Virol. 1993 Aug;67(8):4630–4638. doi: 10.1128/jvi.67.8.4630-4638.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Weeks-Levy C., Tatem J. M., DiMichele S. J., Waterfield W., Georgiu A. F., Mento S. J. Identification and characterization of a new base substitution in the vaccine strain of Sabin 3 poliovirus. Virology. 1991 Dec;185(2):934–937. doi: 10.1016/0042-6822(91)90576-w. [DOI] [PubMed] [Google Scholar]
  30. Westrop G. D., Wareham K. A., Evans D. M., Dunn G., Minor P. D., Magrath D. I., Taffs F., Marsden S., Skinner M. A., Schild G. C. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol. 1989 Mar;63(3):1338–1344. doi: 10.1128/jvi.63.3.1338-1344.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES